"Situé à Massy et à Quincy sous Sénart, l'ICPS centre de référence dans le diagnostic et le traitement des maladies cardiovasculaires. Ses installations de pointe, ses médecins, son personnel médical, son centre de recherche clinique représentent les principaux gages de son excellence. La qualité des soins dispensés valent à l’ICPS une reconnaissance de ses pairs, lui permettant de travailler en partenariat étroit avec les meilleurs spécialistes internationaux de la profession."

During the past decade, Institut Cardiovasculaire Paris-Sud conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 1 clinical trials were completed. i.e. 50% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut Cardiovasculaire Paris-Sud" #1 sponsor was "Boston Scientific Corporation" with 2 trials, followed by "Aarhus University Hospital Skejby" with 1 trials sponsored, "CardioKinetix, Inc" with 1 trials sponsored, "Centre Hospitalier Universitaire de Besancon" with 1 trials sponsored and "Cordis Corporation" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut Cardiovasculaire Paris-Sud" #1 collaborator was "Abbott" with 1 trials as a collaborator, "Asahi Intecc Co., Ltd." with 1 trials as a collaborator, "Biosensors International" with 1 trials as a collaborator, "Boston Scientific Corporation" with 1 trials as a collaborator and "Cardialysis BV" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Institut Cardiovasculaire Paris-Sud" are "Coronary Artery Disease" (3 trials), "Myocardial Infarction" (2 trials), "Atrial Fibrillation" (1 trials), "Chronic Stable Angina" (1 trials) and "Coronary Arteriosclerosis" (1 trials). Many other conditions were trialed in "Institut Cardiovasculaire Paris-Sud" in a lesser frequency.

Most popular intervention types in "Institut Cardiovasculaire Paris-Sud" are "Device" (8 trials), "Other" (3 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Additional support for preoperative planning of LAA closure procedures" (1 trials), "Angioguard distal protection device" (1 trials), "Angioplasty (PROMUS Element™, and Xience™ Prime stent)" (1 trials), "Biolimus-eluting stent implantation" (1 trials) and "Coronary Artery Bypass Surgery" (1 trials). Other intervention names were less common.

The vast majority of trials in "Institut Cardiovasculaire Paris-Sud" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Institut Cardiovasculaire Paris-Sud". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Institut Cardiovasculaire Paris-Sud, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Institut Cardiovasculaire Paris-Sud, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 4 trials that are defined as “Not Applicable".

Institut Cardiovasculaire Paris-Sud has several departments that took part in Clinical trials: "Institut Hospitalier Jacques Cartier Service d'Angiographie, Inst Cardiovasculaire Paris-Sud" - 2 trials